Tae Mo Chung

Learn More
This paper reviews the current and most neurological (central nervous system, CNS) uses of the botulinum neurotoxin type A. The effect of these toxins at neuromuscular junction lends themselves to neurological diseases of muscle overactivity, particularly abnormalities of muscle control. There are seven serotypes of the toxin, each with a specific activity(More)
Treatment of dystonias is generally symptomatic. To produce sufficient therapy effects, therefore, frequently a multimodal and interdisciplinary therapeutic approach becomes necessary, combining botulinum toxin therapy, deep brain stimulation, oral antidystonic drugs, adjuvant drugs and rehabilitation therapy including physiotherapy, occupational therapy,(More)
We used an assembly of electrodes C3 and C4-Cz in order to activate the motor cortical area of the corticobulbar tract to elucidate the motor-evoked potential of the contralateral mentalis muscle. We compared this setup to that of an assembly with electrodes C5 or C6-Cz using a train of electrical pulses and a single electrical pulse. This analysis was made(More)
1 Physiatrist and clinical Neurophysiologist at the Physical Medicine and Rehabilitation Institute HCFMUSP. 2 Psychiatrist, Professor, and Chief of the Psychiatry and Medical Psychology Department at the Faculdade de Ciências Médicas da Santa Casa de São Paulo (São Paulo Santa Casa School of Medical Sciences). 3 Physiatrist, Masters in Sciencies, Physical(More)
Botulinum toxin is a well-established treatment for a number of conditions involving muscle hyperactivity, such as focal dystonia and spastic paresis. However, current injection practice is not standardized and there is a clear need for structured training. An international group of experts in the management of patients with cervical dystonia (CD) and(More)
juice of hibiscus. Logistic regression analysis revealed no relation between use of AM and gender, age, family history of AD, atopy, total number of admittance to health care due to AD, impact of AD on quality of life, parental educational background, SCORAD index, and serum IgE levels. Alternative treatment modalities change in different cultures and(More)
Botulinum toxin (BT) therapy is an established treatment of spasticity due to stroke. For multiple sclerosis (MS) spasticity this is not the case. IAB-Interdisciplinary Working Group for Movement Disorders formed a task force to explore the use of BT therapy for treatment of MS spasticity. A formalised PubMed literature search produced 55 publications (3(More)
  • 1